Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease (HEART)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00487630
First received: June 15, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted
  Purpose

Fabry disease (OMIM 301500) is an X-linked inborn error of sphingolipid metabolism resulting from the deficiency of the lysosomal enzyme alpha-galactosidase A. Heterozygous females for Fabry disease may be symptomatic with cardiac, renal or cerebrovascular involvement. Clearance of Gb3 and stabilization of renal function has been demonstrated in male patients treated with agalsidase beta (FABRAZYME). In contrast, no randomized, controlled study of the efficacy of recombinant alpha-galactosidase A has been reported in heterozygotes for Fabry disease.


Condition Intervention Phase
Fabry Disease
Drug: recombinant alpha-galactosidase A
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Left ventricular mass [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Posterior wall thickness, interventricular thickness, ECG, creatinaemia, urinary protein / creatinine ratio, microalbuminuria, urinary Gb3 level [ Time Frame: 2 years ]

Estimated Enrollment: 34
Study Start Date: June 2005
Estimated Study Completion Date: June 2009
Detailed Description:

The primary objective is to evaluate cardiac left ventricular mass (measured with echocardiography by unique investigator) in females over 15 years of age affected with Fabry disease receiving 70 mg of agalsidase beta every other week, as compared with an untreated controlled group matched for gender and age.

The secondary objectives include evaluation of :

  • left ventricular posterior wall thickness (echocardiography)
  • interventricular septum thickness (echocardiography)
  • tissue doppler imaging (myocardial function)
  • EKG
  • creatinaemia
  • serum cystatin C level
  • urinary protein/creatinine ratio
  • microalbuminuria
  • Gb3 urinary levels

Evaluation of tolerance and safety with :

  • Home therapy infusions follow up
  • Vitals
  • Physical examination
  • Adverse events
  • Antibodies levels
  Eligibility

Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patients over 15 years with clinical and biological evidence of Fabry disease (GLA gene mutation detected)

Exclusion Criteria:

  • Pregnancy
  • Allergy to agalsidase beta
  • Congestive heart failure
  • Creatinaemia > 135 µmol/l
  • Medical history of stroke during the last year
  • Medical history of more than 2 transient ischemic attack
  • Blood pressure > 160/95
  • Modification in medications treating for blood pressure during the last 3 months before enrollment
  • Complete absence of clinical or biological symptoms
  • Weight > 87 kg or < 35 kg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00487630

Contacts
Contact: Dominique P GERMAIN, MD, PhD +33156092306 dominique.germain@egp.aphp.fr
Contact: Karelle BENISTAN, MD +33156092802 karelle.benistan@egp.aphp.fr

Locations
France
Centre de reference de la maladie de Fabry et des maladies hereditaires du tissu conjonctif. Assistance Publique - Hôpitaux de Paris Recruiting
Paris, France
Principal Investigator: Dominique P GERMAIN, MD, PhD         
Sub-Investigator: Karelle BENISTAN, MD         
Sub-Investigator: Albert A HAGEGE, MD, PhD         
Sub-Investigator: Gilles CHATELLIER, MD, PhD         
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Dominique P GERMAIN, MD, PhD Centre de reference de la maladie de Fabry et des maladies hereditaires du tissu conjonctif. Assistance Publique Hopitaux de Paris
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00487630     History of Changes
Other Study ID Numbers: AOM-01-076, PHRC National 2001
Study First Received: June 15, 2007
Last Updated: June 15, 2007
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Heterozygous females
Cardiomyopathy

Additional relevant MeSH terms:
Fabry Disease
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Cardiovascular Diseases
Central Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lipidoses
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Sphingolipidoses
Vascular Diseases

ClinicalTrials.gov processed this record on November 20, 2014